NCE-1 Intelligence & Market Opportunity

Exxua

Gepirone

Antidepressant

Extended Release Tablets

Exxua is an extended-release oral antidepressant for adults with major depressive disorder. It selectively activates serotonin 5‑HT1A receptors, offering symptom relief with low risk of sexual side effects.

Approval Date

22-Sep-23

NCE-1 Date

22-Sep-27

NCE Date

22-Sep-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

135

2029

165

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Gepirone

Innovator

FABRE KRAMER PHARMACEUTICALS INC

Dosage Form

Extended Release Tablets

Strength

18.2 mg, 36.3 mg, 54.5 mg and 72.6 mg

Therapeutic Category

Antidepressant

Usage

To treat major depressive disorder

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets